Rhythm Pharmaceuticals
RYTM
115 hedge funds and large institutions have $851M invested in Rhythm Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 25 increasing their positions, 38 reducing their positions, and 9 closing their positions.
267% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 9
26% more funds holding
Funds holding: 91 → 115 (+24)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4.58% less ownership
Funds ownership: 93.53% → 88.96% (-4.6%)
8% less capital invested
Capital invested by funds: $920M → $851M (-$69M)
34% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 38
52% less call options, than puts
Call options by funds: $892K | Put options by funds: $1.86M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SG Americas Securities
New York
|
+$2.07M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.36M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$963K |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
+$848K |
| 5 |
Primecap Management
Pasadena,
California
|
+$685K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$13.1M |
| 2 |
State Street
Boston,
Massachusetts
|
-$5.79M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$5.29M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$5.25M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.1M |
RYTM Hedge Fund Activity: Q3 2020 in Review
115 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q3 2020, worth a combined $851M — down 7.5% from $920M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new RYTM positions and 9 closed out — a net gain of 24 holders — while 25 added to existing stakes and 38 trimmed.
The largest buyer was SG Americas Securities, opening a new position worth an estimated $2.07M. The largest seller was Deerfield Management, cutting an estimated $13.1M.
- 115 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q3 2020, up from 91 in Q2 2020.
- Funds reported $851M of Rhythm Pharmaceuticals stock for Q3 2020, down 7.5% quarter-over-quarter.
- 33 funds opened new Rhythm Pharmaceuticals positions in Q3 2020 and 9 closed out, a net change of +24 holders.
- The largest Rhythm Pharmaceuticals buyer in Q3 2020 was SG Americas Securities, an estimated $2.07M added.
- The largest Rhythm Pharmaceuticals seller in Q3 2020 was Deerfield Management, an estimated $13.1M sold.
Based on aggregated 13F filings for Q3 2020.